• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    IDEAYA Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    2/17/26 6:04:02 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IDYA alert in real time by email
    8-K
    false000167672500016767252026-02-172026-02-17

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): February 17, 2026

    IDEAYA Biosciences, Inc.

    (Exact name of registrant as specified in its charter)

    Delaware

    001-38915

    47-4268251

    (State or other jurisdiction

    of incorporation)

    (Commission

    File Number)

    (IRS Employer

    Identification Number)

     

    5000 Shoreline Court, Suite 300

    South San Francisco, California 94080
    (Address of principal executive offices, including Zip Code)

     

    Registrant’s telephone number, including area code: (650) 443-6209

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered or to be registered pursuant to Section 12(b) of the Act.

     

    Title of each class

     

    Trading Symbol

     

    Name of each exchange on which registered

    Common Stock, $0.0001 par value per share

     

    IDYA

     

    The Nasdaq Global Select Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


     

    Item 2.02 Results of Operations and Financial Condition.

    On February 17, 2026, IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

    The information in this Item 2.02 and the attached Exhibit 99.1 are being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

    Exhibit No.

     

    Description

     

     

     

    99.1

     

    Press Release dated February 17, 2026.

     

     

     

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    IDEAYA BIOSCIENCES, INC.

     

     

     

    Date: February 17, 2026

    By:

    /s/ Yujiro Hata

     

     

    Yujiro Hata

     

     

    President and Chief Executive Officer

     

     


    Get the next $IDYA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IDYA

    DatePrice TargetRatingAnalyst
    1/7/2026$50.00Buy
    UBS
    11/24/2025Buy
    Truist
    9/18/2025$50.00Buy
    Guggenheim
    9/4/2025$40.00Overweight
    Barclays
    9/4/2025$41.00Mkt Outperform
    Citizens JMP
    7/22/2025Buy
    TD Cowen
    7/10/2025$25.00Neutral
    Goldman
    6/26/2025$44.00Overweight
    Wells Fargo
    More analyst ratings

    $IDYA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Stein Jeffrey bought $1,647,890 worth of shares (50,000 units at $32.96), increasing direct ownership by 1,168% to 54,281 units (SEC Form 4)

    4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)

    3/2/26 7:18:09 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IDYA
    SEC Filings

    View All

    SEC Form 8-K filed by IDEAYA Biosciences Inc.

    8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer)

    4/9/26 6:01:39 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by IDEAYA Biosciences Inc.

    SCHEDULE 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)

    3/27/26 9:55:49 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by IDEAYA Biosciences Inc.

    S-8 - IDEAYA Biosciences, Inc. (0001676725) (Filer)

    2/17/26 4:55:19 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IDYA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Stein Jeffrey bought $1,647,890 worth of shares (50,000 units at $32.96), increasing direct ownership by 1,168% to 54,281 units (SEC Form 4)

    4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)

    3/2/26 7:18:09 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Bleharski Joshua

    4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)

    2/2/26 8:05:22 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Scientific Officer White Michael Anthony

    4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)

    2/2/26 8:03:52 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IDYA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026

    SOUTH SAN FRANCISCO, Calif., April 10, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company, today announced plans to issue a joint IDEAYA and Servier pre-market press release and host a conference call and webcast on Monday, April 13, 2026 at 8:00 a.m. ET to disclose topline results from their ongoing Phase 2/3 registrational trial, OptimUM-02, evaluating darovasertib in combination with crizotinib in patients with first-line HLA*A2-negative metastatic uveal melanoma. The call will include members of IDEAYA's management joined by a distinguished key opinion leader.

    4/10/26 4:05:00 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer

    Potential first-in-class and selective equipotent dual inhibitor of KAT6/7 with single-digit to low teens nano-molar cellular potency in target engagement assays against KAT6 and KAT7, and ~350-to-2,000-fold selectivity over the KAT5 and KAT8 paralogsKAT6/7 dual inhibitor demonstrates greater monotherapy efficacy and durability than KAT6 selective inhibitors in preclinical CDX and PDX modelsMultiple combination opportunities with IDE574 and IDEAYA's proprietary pipelinePotential first-in-class and best-in-class preclinical profile will be presented at AACR 2026SOUTH SAN FRANCISCO, Calif., April 6, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncol

    4/6/26 6:00:00 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma

    FPI achieved for first-in-class combination of IDE849 (DLL3 TOP1 ADC) and IDE161 (PARG inhibitor). IDE161 (PARG) induced accumulation of TOP1 lesions enhances the efficacy and durability of TOP1 ADCs in multiple preclinical modelsIDE849 Phase 1 study advancing globally to determine RP2D, including current dose evaluation at 3.5 mg/kg IV Q3W. Multiple PRs observed at 2.4 mg/kg IV Q3W expansion cohort, including 3 PRs out of 4 SCLC patients pre-treated with IMDELLTRA®Targeting IDE849 monotherapy, and IDE849 and IDE161 combination clinical data update in H2 2026SOUTH SAN FRANCISCO, Calif., March 30, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology compa

    3/30/26 6:00:00 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IDYA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS resumed coverage on IDEAYA Biosciences with a new price target

    UBS resumed coverage of IDEAYA Biosciences with a rating of Buy and set a new price target of $50.00

    1/7/26 9:46:25 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on IDEAYA Biosciences

    Truist initiated coverage of IDEAYA Biosciences with a rating of Buy

    11/24/25 8:30:36 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on IDEAYA Biosciences with a new price target

    Guggenheim initiated coverage of IDEAYA Biosciences with a rating of Buy and set a new price target of $50.00

    9/18/25 8:43:36 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IDYA
    Leadership Updates

    Live Leadership Updates

    View All

    IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer

    SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, today announced the appointment of Dr. Theodora (Theo) Ross into the newly created role of Chief Development Officer. In this role, Dr. Ross will be responsible for leading early clinical development for IDEAYA's emerging oncology pipeline and play a crucial role in guiding the company's long-term R&D strategy. Dr. Ross joins IDEAYA from AbbVie, where she served as Vice President, Head of Early Oncology R&D and Site Head for the Bay Area. 

    2/23/26 6:00:00 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer

    SOUTH SAN FRANCISCO, Calif., Feb. 10, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the appointment of Joshua Bleharski, Ph.D. as Chief Financial Officer.  Dr. Bleharski joins IDEAYA from J.P. Morgan, where he spent nearly 17 years advising clients in the biopharma sector on capital markets transactions, corporate strategy and other investment banking services. IDEAYA anticipates that Dr. Bleharski will complete the transition into his new role by early May. 

    2/10/25 6:00:00 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IDYA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by IDEAYA Biosciences Inc.

    SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)

    11/14/24 4:23:02 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by IDEAYA Biosciences Inc.

    SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)

    11/14/24 3:13:37 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by IDEAYA Biosciences Inc.

    SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)

    11/14/24 1:22:38 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IDYA
    Financials

    Live finance-specific insights

    View All

    IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026

    SOUTH SAN FRANCISCO, Calif., April 10, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company, today announced plans to issue a joint IDEAYA and Servier pre-market press release and host a conference call and webcast on Monday, April 13, 2026 at 8:00 a.m. ET to disclose topline results from their ongoing Phase 2/3 registrational trial, OptimUM-02, evaluating darovasertib in combination with crizotinib in patients with first-line HLA*A2-negative metastatic uveal melanoma. The call will include members of IDEAYA's management joined by a distinguished key opinion leader.

    4/10/26 4:05:00 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma

    Phase 2 company-sponsored and IST neoadjuvant uveal melanoma (UM) clinical data update in 49 evaluable patients, demonstrates ~49% of patients with >30% tumor shrinkage by product of diameters, and ~61% eye preservation rate for enucleation patientsTargeting to initiate Phase 3 randomized registrational trial in neoadjuvant UM following finalization of the clinical protocol with FDAClinical endpoints supportive of full approval based on FDA guidance: Eye preservation rate as the primary endpoint for enucleation patients. Time to vision loss as the primary endpoint for plaque brachytherapy patients. No detriment to Event-Free-Survival (EFS) in the treatment arms is a secondary endpointDiscuss

    9/23/24 6:00:00 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024

    SOUTH SAN FRANCISCO, Calif., Sept. 22, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that the company plans to issue a pre-market press release and conduct an investor webcast on Monday, September 23, 2024, at 8:00 a.m. ET to report interim Phase 2 data for darovasertib and provide a regulatory update from FDA Type C meeting in neoadjuvant uveal melanoma (UM). Darovasertib is a potent and selective protein kinase C (PKC) inhibitor being developed to broadly address primary and metastatic UM.

    9/22/24 9:00:00 AM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care